SCHEMBL5215515

SCHEMBL5215515

CCC(CC)(c1ccccc1NC(=O)CCc1oc(-n2cnc3ccccc32)nc1-c1ccc(C(F)(F)F)cc1)P(=O)(O)O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
GAA P10253 4/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.35
NR2E1 Q9Y466 1/20 0.34
NTRK1 P04629 1/20 0.34
NTRK2 Q16620 1/20 0.34
POLB P06746 2/20 0.33
KDM4E B2RXH2 2/20 0.33
KMT2A Q03164 2/20 0.33
OPRK1 P41145 1/20 0.33
HDAC1 Q13547 1/20 0.33
AURKA O14965 1/20 0.33
KDR P35968 1/20 0.33
AURKB Q96GD4 1/20 0.33
MKNK2 Q9HBH9 2/20 0.33
TRPV1 Q8NER1 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211132 0.88 POLB (0.34) ALDH1A1HPGDTSHRPOLBKDM4E
SCHEMBL5210939 0.87 KMT2A (0.34) ALDH1A1TSHRPOLBKDM4EKMT2A
SCHEMBL5213983 0.84 CNR2 (0.38) ALDH1A1GAALMNAHPGDPOLB
SCHEMBL5212555 0.84 TNKS (0.38) ALDH1A1LMNAHPGDNR2E1POLB
SCHEMBL5207013 0.83 MAPT (0.39) ALDH1A1LMNAHPGDPOLB
SCHEMBL5213373 0.83 ALDH1A1 (0.35) ALDH1A1LMNAPOLBKDM4EKMT2A
SCHEMBL5212127 0.82 SMN1; SMN2 (0.40) ALDH1A1GAAHPGDKDM4EKMT2A
SCHEMBL5208381 0.80 TP53 (0.34) LMNAPOLBKMT2A
SCHEMBL5210803 0.80 AURKA (0.43) ALDH1A1LMNAHPGDAURKAKDR
SCHEMBL5210300 0.80 TP53 (0.35) ALDH1A1GAAPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 ALDH1A1 1651/4885GAA 4803/4885LMNA 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.